The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions
Open accessAbstract
Background and objective: The real‐world tolerability of pirfenidone and nintedanib in non‐clinical trial patients is unknown. Many patients with pulmonary fibrosis have significant medical co‐morbidities or baseline characteristics that exclude them from clinical trial participation. Methods: We conducted a retrospective chart review study on subjects prescribed nintedanib or pirfenidone for pulmonary fibrosis treatment (any aetiology) from September 2014 to February 2016. A total of 186 subjects were included: 129 received pirfenidone and 57 were prescribed nintedanib and followed up for mean observation periods of 52 ± 17 weeks for pirfenidone and 41 ± 15 weeks for nintedanib. The primary outcome was drug discontinuation as a result of an adverse event. Results: Subjects had significant respiratory impairment at baseline, 63% required home oxygen therapy and mean diffusion capacity of carbon monoxide (DL CO) was 36 ± 14% predicted. Drug discontinuation as a result of an adverse event occurred in 20.9% of subjects on pirfenidone and 26.3% on nintedanib. Drug discontinuation rates for both pirfenidone and nintedanib did not significantly differ from corresponding large clinical trials (ASCEND/CAPACITY and INPULSIS 1 and 2, respectively). Adverse events that occurred with highest frequency on pirfenidone were nausea (26.4%), rash/photosensitivity (14.7%) and dyspepsia/gastroesophageal reflux disease (GERD) (12.4%). Diarrhoea (52.6%) and nausea (29.8%) were reported most often with nintedanib therapy. Conclusion: Patients with pulmonary fibrosis treated with nintedanib or pirfenidone in routine clinical practice had drug tolerability and adverse event profiles comparable with subjects enrolled in clinical trials despite having a greater degree of respiratory impairment and a high prevalence of co‐morbid medical conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454
Risk factors of acute exacerbation of idiopathic pulmonary fibrosis.
Kondoh, Y., Taniguchi, H., Katsuta, T., Kataoka, K., Kimura, T., Nishiyama, O., Sakamoto, K., Johkoh, T., Nishimura, M., Ono, K., et al. (2010) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 191
Cottin, V., & Maher, T. M. (2015) · European Respiratory Review · doi:10.1183/09059180.00011514 · Cited by 132
Oltmanns, U., Kahn, N. C., Palmowski, K., Träger, A., Wenz, H., Heußel, C. P., Schnabel, P. A., Puderbach, M., Wiebel, M., Ehlers-Tenenbaum, S., et al. (2014) · Respiration · doi:10.1159/000363064 · Cited by 130
Valeyre, D., Albera, C., Bradford, W. Z., Costabel, U., King, T. E., Leff, J. A., Noble, P. W., Sahn, S. A., & du Bois, R. M. (2014) · Respirology · doi:10.1111/resp.12297 · Cited by 116
Risk Factors For Acute Exacerbation Of Idiopathic Pulmonary Fibrosis
Kondoh, Y., Taniguchi, H., Katsuta, T., Kimura, T., Kataoka, K., Taga, S., Johkoh, T., & Kitaichi, M. (2010) · doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1107 · Cited by 109
Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice
Okuda, R., Hagiwara, E., Baba, T., Kitamura, H., Kato, T., & Ogura, T. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.06.011 · Cited by 98
Ogura, T., Azuma, A., Inoue, Y., Taniguchi, H., Chida, K., Bando, M., Niimi, Y., Kakutani, S., Suga, M., Sugiyama, Y., et al. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.06.001 · Cited by 79
Real world experiences: Pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis
Chaudhuri, N., Duck, A., Frank, R., Holme, J., & Leonard, C. T. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.11.005 · Cited by 75
Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis
Bando, M., Yamauchi, H., Ogura, T., Taniguchi, H., Watanabe, K., Azuma, A., Homma, S. A., & Sugiyama, Y. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.5272 · Cited by 72
Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis
Arai, T., Inoue, Y., Sasaki, Y., Tachibana, K., Nakao, K., Sugimoto, C., Okuma, T., Akira, M., Kitaichi, M., & Hayashi, S. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.09.002 · Cited by 50
Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
Bonella, F., Wessendorf, T., & Costabel, U. (2013) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0032-1332930 · Cited by 48
Wijsenbeek, M. S., Grutters, J. C., & Wuyts, W. A. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0225-1 · Cited by 35
Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
Bonella, F., Wessendorf, T., & Costabel, U. (2013) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0032-1330179 · Cited by 19
Cited by
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Spagnolo, P., Kropski, J. A., Jones, M. G., Lee, J. S., Rossi, G., Karampitsakos, T., Maher, T. M., Tzouvelekis, A., & Ryerson, C. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107798 · Cited by 636
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
Wang, J., Hu, K., Cai, X., Yang, B., He, Q., Wang, J., & Weng, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.023 · Cited by 450
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S., Creamer, A., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 382
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017) · European Respiratory Review · doi:10.1183/16000617.0057-2017 · Cited by 295
Richeldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30262-0 · Cited by 293
Metadata
- Authors
- Galli, J. A., Pandya, A., Vega‐Olivo, M., Dass, C., Zhao, H., & Criner, G. J.
- Venue
- Respirology
- Publisher
- Wiley
- Published
- 2017-03-20
- Volume
- 22
- Issue
- 6
- Pages
- 1171-1178
- ISSN
- 1323-7799 (ISSN-L)
- 1440-1843
- OpenAlex
- W2597638604
- Cited by
- 257
- References
- 24
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.